Tryptamine Therapeutics (ASX:TYP) will start supplying its psilocin-based drug, TRP-8803, to Swinburne University as part of a clinical trial targeting binge eating disorder, following the university's receipt of a permit to obtain controlled substances for research, according to a Thursday filing with the Australian bourse.

Several trial candidates have now completed the preliminary screening process and are scheduled for interviews next week, to be followed by initial enrollments, the filing said.

Shares of the company rose past 3% in recent Thursday trade.